1. history of laboratory-confirmed sars-cov-2 infection or sars-cov-2 seropositivity at screening. 2. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 3. known history of allergy or reaction to any component of the study drug formulation. 4. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 5. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow up. 6. clinically significant bleeding disorder or prior history of significant bleeding or bruising following im injections or venipuncture. 7. any other significant disease, disorder, or finding that, in the judgement of the investigator, may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 8. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study. 9. currently pregnant or breast feeding. 10. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 11. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 12. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

1. history of laboratory-confirmed sars-cov-2 infection or sars-cov-2 seropositivity at screening. 2. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 3. known history of allergy or reaction to any component of the study drug formulation. 4. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 5. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow up. 6. clinically significant bleeding disorder or prior history of significant bleeding or bruising following im injections or venipuncture. 7. any other significant disease, disorder, or finding that, in the judgement of the investigator, may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 8. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study. 9. currently pregnant or breast feeding. 10. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 11. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 12. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

history of laboratory-confirmed sars-cov-2 infection or sars-cov-2 seropositivity at screening. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). known history of allergy or reaction to any component of the study drug formulation. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow up. clinically significant bleeding disorder or prior history of significant bleeding or bruising following im injections or venipuncture. any other significant disease, disorder, or finding that, in the judgement of the investigator, may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study. currently pregnant or breast feeding. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

history of laboratory-confirmed sars-cov-2 infection or sars-cov-2 seropositivity at screening. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). known history of allergy or reaction to any component of the study drug formulation. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow up. clinically significant bleeding disorder or prior history of significant bleeding or bruising following im injections or venipuncture. any other significant disease, disorder, or finding that, in the judgement of the investigator, may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study. currently pregnant or breast feeding. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

1. history of laboratory-confirmed sars-cov-2 infection or sars-cov-2 seropositivity at screening. 2. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 3. known history of allergy or reaction to any component of the study drug formulation. 4. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 5. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow up. 6. clinically significant bleeding disorder or prior history of significant bleeding or bruising following im injections or venipuncture. 7. any other significant disease, disorder, or finding that, in the judgement of the investigator, may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 8. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study. 9. currently pregnant or breast feeding. 10. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 11. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 12. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

1. history of laboratory-confirmed sars-cov-2 infection or sars-cov-2 seropositivity at screening. 2. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 3. known history of allergy or reaction to any component of the study drug formulation. 4. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 5. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow up. 6. clinically significant bleeding disorder or prior history of significant bleeding or bruising following im injections or venipuncture. 7. any other significant disease, disorder, or finding that, in the judgement of the investigator, may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 8. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study. 9. currently pregnant or breast feeding. 10. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 11. employees of the sponsor involved in planning, executing, supervising, or reviewing the azd7442 program, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 12. in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

1. history of laboratory-confirmed sars-cov-2 infection or sars-cov-2 seropositivity at screening. 2. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 3. known history of allergy or reaction to any component of the study drug formulation. 4. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 5. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow up. 6. clinically significant bleeding disorder or prior history of significant bleeding or bruising following im injections or venipuncture. 7. any other significant disease, disorder, or finding that, in the judgement of the investigator, may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 8. receipt of blood products or immunoglobulins, including mabs, within 6 months, or 5 antibody half-lives if longer than 6 months, prior to screening. 9. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study. 10. currently pregnant or breast feeding. 11. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 12. employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.

1. history of laboratory-confirmed sars-cov-2 infection or sars-cov-2 seropositivity at screening. 2. history of infection with severe acute respiratory syndrome (sars) or middle east respiratory syndrome (mers). 3. known history of allergy or reaction to any component of the study drug formulation. 4. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 5. any prior receipt of investigational or licensed vaccine or other mab/biologic indicated for the prevention of sars-cov-2 or covid-19 or expected receipt during the period of study follow up. 6. clinically significant bleeding disorder or prior history of significant bleeding or bruising following im injections or venipuncture. 7. any other significant disease, disorder, or finding that, in the judgement of the investigator, may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data. 8. receipt of blood products or immunoglobulins, including mabs, within 6 months, or 5 antibody half-lives if longer than 6 months, prior to screening. 9. receipt of any imp in the preceding 90 days or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study. 10. currently pregnant or breast feeding. 11. blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 12. employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.